EUVIMEDEUVIMED entdecken
Crossref

Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide

Takehiro Miyagi, Daiki Tsuji iD, Eiji Nakatani, Yuri Sahara-Ishino, Chika Kodama, Umi Tokou, Kunihiko Itoh

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Takehiro Miyagi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, University of Shizuoka academic research grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chemotherapy‐induced neutropenia (CIN) and febrile neutropenia (FN) are important considerations for anticancer drug dosing. Recent studies suggest that CIN may also improve survival. This study aimed to assess the impact of CIN on survival outcomes in breast cancer patients and to develop a predictive model for CIN incorporating genetic factors.

Methods

In 166 breast cancer patients treated with doxorubicin and cyclophosphamide (AC therapy), neutropenia was classified into three severity groups using CTCAE v5.0 criteria. The relationship between severe CIN and survival was analysed. Additionally, 33 genetic polymorphisms linked to pharmacokinetics and susceptibility were examined, and a predictive model for CIN was built using multivariate logistic regression integrating clinical and genetic factors.

Results

Among patients receiving AC therapy, the 10‐year survival rates were 80.6% for the Grades 0–2 group, 96.2% for the Grades 3–4 group without FN, and 79.0% for the Grades 3–4 group with FN, indicating that patients in the Grades 3–4 group without FN had significantly longer survival. A predictive model for Grade 4 CIN was developed using seven factors: age, haemoglobin levels, serum creatinine levels, and the genetic polymorphisms ABCB1 rs1128503, ERCC1 rs11615, ERCC2 rs238406 and XRCC3 rs709399. The model had an AUC of 0.744 (95% CI, 0.666–0.823), and including genetic polymorphisms improved predictive accuracy by 0.128 ( P = 0.004).

Conclusions

CIN was linked to improved survival in breast cancer patients. The predictive model including genetic factors provided a more accurate assessment of CIN risk, potentially enabling more personalized treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinNeutropeniaAdultAgedFemaleHumansMiddle AgedJapanPolymorphism, Single NucleotideRisk FactorsEast Asian People

Stichwörter der Autor:innen

AC therapybreast cancerneutropeniapharmacogenomicspredictive modelling

Substanzen

CyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Biostatistics and Health Data Science, Graduate School of Medical Science Nagoya City University, Nagoya, Japan.
  • Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
  • Department of Pharmacy, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
  • Ain Pharmacy Nippon Medical School Musashi Kosugi Hospital, Japan.

ORCID-Profile: Daiki Tsuji

Förderung

  • Japan Society for the Promotion of Science
  • University of Shizuoka academic research grant

Zitieren

APA

Miyagi, T., Tsuji, D., Nakatani, E., Sahara-Ishino, Y., Kodama, C., Tokou, U., & Itoh, K. (2026). Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70259

Vancouver

Miyagi T, Tsuji D, Nakatani E, Sahara-Ishino Y, Kodama C, Tokou U, et al. Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70259

BibTeX
@article{Miyagi2026,
  author = {Miyagi, Takehiro and Tsuji, Daiki and Nakatani, Eiji and Sahara-Ishino, Yuri and Kodama, Chika and Tokou, Umi and Itoh, Kunihiko},
  title = {Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70259}
}
Kostenlos starten →